After finishing in 2nd place in 2023, Roche returned to the top of the CNS Summit Digital Innovation Index in 2024, thanks to impressive achievements in the commercial and clinical fields. With notable advancements in remote patient monitoring via wearables and multiple innovative collaborations fueled through AI, Roche secured its third 1st place finish in the past four years.

Roche continued to venture into the popular field of AI this year, engaging in collaborations with Ibex Medical Analytics and PathAI. The former partnership resulted in the development of AI algorithms that directly support clinicians in diagnosing both breast and prostate cancers, enabling laboratories to streamline their diagnostic processes and create a sustainable ecosystem for pathological laboratories. ​

Roche’s collaboration with PathAI also focused on enhancing its pathological algorithms, with a specific emphasis on Roche Tissue Diagnostics and companion diagnostics. These collaborations underscore Roche’s commitment to advancing the field of digital pathology and AI-enabled diagnostics for both drug development and clinical care, with the ultimate goal of improving patient care and advancing personalized healthcare through AI-enabled solutions.

One of Roche’s marquee achievements of the past year was the development of a continuous glucose monitor powered by predictive algorithms. The Accu-Chek SmartGuide uses machine learning to support patients with accurate predictions and easier management of hypoglycemia risk.

The SmartGuide device piqued interest in the cardiovascular space—sparking a collaboration with CardioSignal’s motion sensor technology to support heart disease detection, in particular underlying asymptomatic heart conditions.

Outside of the world of AI, Roche’s Navify Digital Solutions received positive reviews from the KLAS Research board. KLAS Research is an esteemed independent organization that assesses healthcare technology solutions based on performance and customer satisfaction, making their recognition a significant endorsement in the industry.

Another of Roche’s notable non-AI stories of this last year was its collaboration with the Sustainable Healthcare Coalition to invest in the development of digital methodologies and databases that will enable sponsors to measure the carbon footprint of its clinical trial, with the intention of pinpointing ways to decarbonize those trials.

In 2024, Roche reaffirmed its leadership in digital health through AI-driven innovations, strategic partnerships, and advancements in patient care technologies. These achievements highlight Roche’s commitment to personalized healthcare and sustainable clinical practices, solidifying its role as a pioneer in the future of medicine.